Key result
A drug for severe sepsis was withdrawn from the market after failing to reduce mortality.
A severe sepsis drug has been withdrawn from the market due to lack of mortality benefit.
Answers are grounded in this paper and cite their sources.
Emphasizes mortality endpoints in sepsis trials; leaves open optimal designs for future agent development.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mike Mitka (2011) studied Severe Sepsis. Drug for Severe Sepsis was evaluated on Mortality. A drug for severe sepsis was withdrawn from the market after failing to reduce mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: